Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-905 perioperative pembrolizumab versus cystectomy alone in cisplatin-ineligible or cisplatin-declining muscle-invasive bladder cancer
MOH_2019-05-24_007132Phase 3Completed
- Sponsor
- MOH_2019-05-24_007132
- Start
- May 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in bladder cancer and muscle-invasive bladder cancer (MIBC) (3 arms), sponsored by MOH_2019-05-24_007132. Started May 2019; status: completed.
02
Drugs
03
Conditions
bladder cancermuscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on MOH_2019-05-24_007132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-05-24_007132.